TNF Pharmaceuticals
在场
TNF Pharmaceuticals 是一家在股票代码 MYMD (US) 下上市的公司。
高管
查看带有其 9 名主要高管的组织结构图
TNF Pharmaceuticals 搜索最多的简介
- Chris Chapman, President, Director and Chief Medical Officer
- Bill White, Non-Executive Director
- Jude Uzonwanne, Director
高管在TNF Pharmaceuticals变化
- Mitchell Glass 曾任 Director, 现升职为 Director, President and Chief Medical Officer (新闻发布的2024六月18号).
- Stephen Friscia已作为Director加入公司 (新闻发布的2024六月18号).
创建提醒
跟踪 TNF Pharmaceuticals 的高管变动
医疗设备
TNF Pharmaceuticals 拥有 1,005 家竞争者，其中包括 Philips (荷兰)、Medtronic (爱尔兰岛) 和 Thermo Fisher Scientific (美国(美洲))。
Popular M&A news in 医疗设备
- Precision Neuroscience 刚刚宣布为 102 筹款数百万美元。 (公布2024十二月18号).
- electroCore 已收购 NeuroMetrix (公布2024十二月18号).
- Anteris Technologies 刚刚宣布为 89 筹款数百万美元。 (公布2024十二月16号).
医疗设备 行业的其他推荐联系人
消息
TNF Pharmaceuticals 的最新新闻稿
- News
- News
- MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
- MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
- MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
- MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
- BioFuture 2023
- MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
- MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
- Data Planning and Database Lock
- View more press releases Close
